EP1534728A4 - Modulation antisens de l'expression du recepteur de glucocorticoide - Google Patents

Modulation antisens de l'expression du recepteur de glucocorticoide

Info

Publication number
EP1534728A4
EP1534728A4 EP03729073A EP03729073A EP1534728A4 EP 1534728 A4 EP1534728 A4 EP 1534728A4 EP 03729073 A EP03729073 A EP 03729073A EP 03729073 A EP03729073 A EP 03729073A EP 1534728 A4 EP1534728 A4 EP 1534728A4
Authority
EP
European Patent Office
Prior art keywords
glucocorticoid receptor
receptor expression
antisense modulation
expression
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03729073A
Other languages
German (de)
English (en)
Other versions
EP1534728A2 (fr
Inventor
Seth D Crosby
Amy E Nalseth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of EP1534728A2 publication Critical patent/EP1534728A2/fr
Publication of EP1534728A4 publication Critical patent/EP1534728A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a trait à des compositions et des procédés permettant la modulation de l'expression du récepteur de glucocorticoïde mammalien. En particulier, l'invention a trait à des composés antisens, notamment des oligonucléotides, d'hybridation spécifique avec des acides nucléiques codant pour le récepteur de glucocorticoïde humain.
EP03729073A 2002-05-20 2003-05-20 Modulation antisens de l'expression du recepteur de glucocorticoide Withdrawn EP1534728A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38185702P 2002-05-20 2002-05-20
US381857P 2002-05-20
PCT/US2003/016084 WO2003099215A2 (fr) 2002-05-20 2003-05-20 Modulation antisens de l'expression du recepteur de glucocorticoide

Publications (2)

Publication Number Publication Date
EP1534728A2 EP1534728A2 (fr) 2005-06-01
EP1534728A4 true EP1534728A4 (fr) 2005-10-26

Family

ID=29584332

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03729073A Withdrawn EP1534728A4 (fr) 2002-05-20 2003-05-20 Modulation antisens de l'expression du recepteur de glucocorticoide

Country Status (4)

Country Link
EP (1) EP1534728A4 (fr)
JP (1) JP2005525829A (fr)
AU (1) AU2003233634A1 (fr)
WO (1) WO2003099215A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050164271A1 (en) * 2004-01-20 2005-07-28 Sanjay Bhanot Modulation of glucocorticoid receptor expression
EP2397563A3 (fr) * 2004-09-17 2012-07-18 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
EP1941040A1 (fr) * 2005-09-19 2008-07-09 Johnson & Johnson Pharmaceutical Research & Development L.L.C. Modulation de l'expression du récepteur glucocorticoïde
CA3044969A1 (fr) 2006-05-05 2007-12-21 Ionis Pharmaceuticals, Inc. Composes et procedes de modulation de l'expression genique
JP2009171895A (ja) * 2008-01-24 2009-08-06 Hitachi Software Eng Co Ltd 核内ノンコーディングｒｎａの機能解析方法
EP2429657A2 (fr) * 2009-05-15 2012-03-21 F. Hoffmann-La Roche AG Compositions et procédés pour l'inhibition de l'expression de gènes de récepteurs aux glucocorticoïdes (gcr)
WO2011113015A2 (fr) * 2010-03-12 2011-09-15 Avi Biopharma, Inc. Modulation anti-sens de récepteurs hormonaux nucléaires
WO2013063313A1 (fr) 2011-10-25 2013-05-02 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression de gccr
US9234200B2 (en) * 2011-12-15 2016-01-12 National University Of Corporation Tokyo University Of Agriculture And Technology Oligonucleotide, glucocorticoid sensitivity enhancer, pharmaceutical composition, and expression vector
WO2016077704A1 (fr) * 2014-11-14 2016-05-19 The Regents Of The University Of California Modulation de l'expression de la protéine angptl5
CN112839671A (zh) * 2018-05-17 2021-05-25 明尼苏达大学董事会 抗药性免疫细胞及其使用方法
BR112023018948A2 (pt) * 2021-03-19 2023-10-17 Metagenomi Inc Edição multiplex com enzimas cas
WO2024245930A2 (fr) * 2023-05-26 2024-12-05 E-Therapeutics Plc Inhibiteurs d'expression et/ou de fonction

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027986A1 (fr) * 1996-12-24 1998-07-02 Zymogenetics, Inc. Agents therapeutiques et procedes de traitement du diabete de type ii et symptomes du diabete de type ii

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027986A1 (fr) * 1996-12-24 1998-07-02 Zymogenetics, Inc. Agents therapeutiques et procedes de traitement du diabete de type ii et symptomes du diabete de type ii

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
29TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE.; MIAMI BEACH, FLORIDA, USA; OCTOBER 23-28, 1999 *
ALTMANN K-H ET AL: "NOVEL CHEMISTRY", APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY, NEW YORK, WILEY-LISS, US, 1998, pages 73 - 107, XP002119324, ISBN: 0-471-17279-0 *
HOLLENBERG S M ET AL: "PRIMARY STRUCTURE AND EXPRESSION OF A FUNCTIONAL HUMAN GLUCOCORTICOID RECEPTOR CDNA", NATURE, vol. 318, 19 December 1985 (1985-12-19), pages 635 - 641, XP000611470, ISSN: 0028-0836 *
ISLAM A ET AL: "Antisense oligodeoxynucleotide to rat glucocorticoid receptor, given ICV in polymer microspheres, reduces glucocorticoid- and increases 5-HT2A-receptor binding", BRITISH JOURNAL OF PHARMACOLOGY, vol. 129, no. Proceedings Supplement, January 2000 (2000-01-01), pages 244P, XP008051733, ISSN: 0007-1188 *
ISLAM A ET AL: "Antisense oligonucleotides to the rat glucocorticoid receptor (GR), optimised by RNase-H accessibility mapping of in vitro transcribed mRNA, modulate GR and 5-HT2A expression in C6 glioma cells", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 25, no. 1-2, 1999, pages 1817, XP008051792, ISSN: 0190-5295 *
MEETING OF THE BRITISH PHARMACOLOGICAL SOCIETY; CAMBRIDGE, ENGLAND, UK; JANUARY 05-07, 2000. *
RICHARDS D ET AL: "Energy balance and lipid metabolism in transgenic mice bearing an antisense GCR gene construct", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 265, no. 1 PART 2, 1993, pages R146 - R150, XP008051596, ISSN: 0002-9513 *

Also Published As

Publication number Publication date
EP1534728A2 (fr) 2005-06-01
AU2003233634A1 (en) 2003-12-12
WO2003099215A2 (fr) 2003-12-04
JP2005525829A (ja) 2005-09-02
WO2003099215A3 (fr) 2005-03-31
AU2003233634A8 (en) 2003-12-12

Similar Documents

Publication Publication Date Title
WO2004005460A3 (fr) Modulation antisens de l'expression de la reductase de hmg-coa
WO2004030750A8 (fr) Modulation antisens de l'expression du fxr (farnesoid x receptor)
WO2003012057A3 (fr) Modulation antisens de l'expression du serum amyloide a4
AU2001290706A1 (en) Antisense modulation of clusterin expression
WO2004044181A3 (fr) Modulation antisens de l'expression d'apolipoproteine b
WO2004011610A3 (fr) Modulation antisens de l'expression de kinase de type polo
WO2004071407A3 (fr) Modulation antisens de l'expression de ptp1b
WO2003097662A8 (fr) Modulation antisens de l'expression de l'apolipoproteine b
WO2003052072A3 (fr) Modulation antisens de l'expression du recepteur alpha d'oestrogene
WO2003010284A3 (fr) Modulation antisens de l'expression de la proteine reactive c
WO2003099215A3 (fr) Modulation antisens de l'expression du recepteur de glucocorticoide
WO2003000656A3 (fr) Modulation anti-sens de l'expression du recepteur du facteur de croissance transformant bêta de type ii
WO2003053341A3 (fr) Modulation antisens de l'expression de ship-1
WO2003057843A3 (fr) Procedes et materiaux de modulation de trpc4
WO2003104397A3 (fr) Modulation antisens de l'expression de la proteine kinase gr 6
WO2002095053A3 (fr) Modulation antisens de l'expression des src-c
WO2003088921A3 (fr) Modulation antisens de l'expression d'hydroxysteroide 11-beta deshydrogenase 1
WO2003050244A3 (fr) Modulation antisens de l'expression de recepteur etbr-lp-2 couple aux proteines g
WO2003052062A3 (fr) Modulation antisens de l'expression de cd36l1
WO2004010956A3 (fr) Modulation par antisens d'expression de lar
WO2003057847A8 (fr) Procedes et substances de modulation de l'enac-beta
WO2003099224A3 (fr) Modulation antisens de l'expression de la kinesine de type 1
WO2004003201A3 (fr) Modulation antisens de l'expression de lrh1
WO2004016749A3 (fr) Modulation antisens de l'expression de l'acyl-coa synthetase 1
WO2004014299A3 (fr) Modulation antisens de l'expression de la resistine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041203

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20050909

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 15/11 A

Ipc: 7A 61K 31/7088 B

Ipc: 7C 07H 21/00 B

Ipc: 7A 61P 3/00 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051124